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ABSTRACT
Introduction: Somatostatin analogs (SSAs) are
used to treat neuroendocrine tumors (NETs) and
acromegaly. Two first-generation SSAs, octreo-
tide long-acting release (OCT LAR) and lan-
reotide autogel/depot (LAN), are available. A
systematic literature review (SLR) was con-
ducted to investigate which characteristics
beyond efficacy are most important in patient
and healthcare practitioner (HCP) experience of
LAN and OCT when used to treat acromegaly
and NETs.
Methods: MEDLINE, Embase, the Cochrane
Library, and Database of Abstracts of Reviews of
Effect were searched from database inception to
January 2019 with terms for first-generation
SSAs, NETs, acromegaly, preferences, decision-
making, and human factors. Key congresses in
2016–2018 and SLR bibliographies were hand-
searched. Two independent reviewers screened
articles at title/abstract and full-text stage.
Publications fulfilling pre-specified inclusion
criteria reported patient or HCP perspectives of
LAN or OCT, or any factors affecting treatment
perspectives for NETs or acromegaly.
Results: A total of 1110 unique records were
screened, of which 21 studies were included,
reporting from the perspectives of patients
(n = 18) and/or HCPs (n = 9). Perspectives were
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collected using shared decision-making frame-
works, questionnaires, informal patient opin-
ion, and a Delphi panel. Where patient
preference was specifically reported, LAN was
preferred in 4/5 studies and OCT LAR in 1/5.
Common factors underlying treatment experi-
ence included technical problems with injec-
tions and associated pain, emotional quality/
anxiety of injections, time and convenience of
treatment administration, and independence.
Immediate aspects of injections appeared most
important to patients, though the possibilities
of extended dosing intervals and self-/partner-
injection with LAN were also notable factors.
Conclusions: Study outcomes favored LAN in
this SLR, with factors surrounding injection
administration most influential in treatment
experience. The findings of this SLR provide a
basis that could inform development of deci-
sion-making criteria, with patient and HCP
treatment perspectives considered. Future stud-
ies should utilize a common method to report
preference and associated drivers.
Keywords: Acromegaly; Neuroendocrine
tumors; Preference; Somatostatin analogs;
Treatment perspectives
Key Summary Points
Why carry out this study?
This manuscript reports the findings of a
systematic literature review (SLR) to
investigate which characteristics of first-
generation somatostatin analogs (SSAs),
beyond efficacy, are most important from
patient and healthcare practitioner (HCP)
perspectives, when used to treat
acromegaly and neuroendocrine tumors.
What was learned from the study?
A total of 26 publications reporting on 21
studies were included in this SLR,
reporting from the perspectives of patients
(n = 18) and HCPs (n = 9), using shared
decision-making frameworks,
questionnaires, informal patient opinion,
and a Delphi panel.
Common factors underlying treatment
experience with long-acting lanreotide
and octreotide included technical
problems with injections and associated
pain, emotional quality/anxiety of
injections, time and convenience of
treatment administration, and patient
independence; immediate aspects of
injection administration appeared most
important to patients.
Where study participants had direct
experience of both SSAs, four of the five
studies reporting patient preference, and
the only study reporting preference of
HCPs, reported preference for lanreotide
autogel over octreotide long-acting
release.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13333565.
INTRODUCTION
Long-acting somatostatin analogs (SSAs) are
used to treat neuroendocrine tumors (NETs)
with and without features of carcinoid syn-
drome (CS), the latter resulting from the
hypersecretion of serotonin and other vasoac-
tive substances from NETs [1–3]. The European
Neuroendocrine Tumor Society (ENETS) and
National Comprehensive Cancer Network
(NCCN) guidelines recommend SSAs as first-line
systemic therapy for unresectable and/or meta-
static gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) following surgery [4, 5].
SSAs are also indicated as primary and adjuvant
treatment for acromegaly, a disorder resulting
from the overproduction of growth hormone
from adenomas, for patients who are unable to
undergo surgery, are not cured by surgery, or
otherwise require medical treatment [6–8]. The
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clinical efficacy and safety of the two first-gen-
eration SSAs lanreotide autogel/depot (LAN)
and octreotide long-acting release (OCT LAR)
has been previously demonstrated; both SSAs
have been shown to decrease growth hormone
and insulin-like growth factor 1 levels in
patients with acromegaly [9–13], as well as to
contribute to progression-free survival in
patients with NETs [14–19].
LAN is approved in countries including Eur-
ope and the USA for long-term treatment of
acromegaly, treatment of gastrointestinal (GI)
NETs and pancreatic NETs, and of symptoms
associated with NETs (EU only) [8, 18]. In Eur-
ope, LAN is also indicated for NETs of unknown
origin and NETs with a Ki-67 index of up to 10%
[8]. LAN is supplied in a pre-filled syringe,
administered by deep subcutaneous injection
once every 4 weeks [20, 21]. Additionally,
extended dosing intervals (EDIs) are available
for patients with acromegaly when symptom
control is stable [18], and this ready-to-use for-
mulation allows for the possibility of self-in-
jection by patients with NETs and acromegaly
in most geographies (self-injection not yet
approved in the USA) [8, 18].
OCT LAR is indicated for long-term treat-
ment of acromegaly in Europe and the USA
[19, 22]. OCT LAR is also approved in Europe for
symptom and tumor control in GI NETs or NETs
of unknown primary origin, and in the USA it is
approved for the treatment of symptoms in
metastatic carcinoid tumors [19, 22]. A short-
acting OCT daily subcutaneous injection for-
mulation was previously used in long-term
treatment of acromegaly and GEP-NETs [23],
though this is now mainly used for prophylaxis
of carcinoid crises prior to surgeries, or as rescue
treatment in the case of acute symptoms. OCT
LAR is provided as a powder that requires
reconstitution in a solvent by a healthcare
practitioner (HCP) before intramuscular injec-
tion [19, 22].
Despite their therapeutic benefits and wide
use in clinical practice over the last two decades,
understanding of which SSA product charac-
teristics beyond efficacy and safety impact the
treatment experience of patients and HCPs is
currently limited. The objective of this SLR was
to identify treatment characteristics that
influence patient and HCP experience of LAN
and OCT LAR when used to treat acromegaly
and NETs. As such, this SLR sought to determine
distinguishing factors between the two SSAs




Databases including MEDLINE, Embase, the
Cochrane Database of Systematic Reviews, the
Database of Abstracts of Reviews of Effect, and
the Cochrane Central Register of Controlled
Trials were searched from database inception to
11 January 2019 using terms for SSAs, NETs or
acromegaly, preferences, decision-making, and
human factors (a full list of search terms can be
found in Tables S1–S4). Terms were decided
through consultation with independent experts
in SLR design and development. Congresses
that had taken place in 2016–2018 including
the North American Neuroendocrine Tumor
Society, European Neuroendocrine Tumour
Society, European Congress of Endocrinology,
Pituitary Society International Congress, and
UK and Ireland Neuroendocrine Tumour Soci-
ety were hand-searched for further evidence
using the search terms based on those used in
the electronic databases, and strategies were
based on the search functions of the individual
conferences. Bibliographies of relevant SLRs
were also hand-searched.
Study Selection and Data Extraction
Abstracts and full texts eligible for inclusion in
this SLR must have been published in English
and reported data pertaining to adult patients
with NETs or acromegaly receiving treatment
with long-acting formulations of LAN or OCT,
or to their HCPs. Studies reported information
regarding treatment experience or SSA prefer-
ence, including but not limited to opinion of
safety, efficacy, direct costs; indirect costs; non-
utility quantitative measures; and qualitative
findings in interviews or focus groups. Full
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eligibility criteria are detailed in Table S5. Two
independent reviewers screened records for
inclusion using the pre-specified criteria at the
title/abstract stage and full-text stage, and any
discrepancies were resolved by discussion until
a consensus was met. If necessary, a third
reviewer made the final decision. Where the
applicability of the inclusion criteria was
unclear, articles were included at the abstract
stage to ensure that all potentially relevant
studies were captured. Articles of unclear rele-
vance could then be excluded at the full-text
stage to ensure that only relevant articles were
ultimately included. Relevant data pertaining to
study design, location, date and duration,
treatment arms, funding, study aims and eligi-
bility criteria, interventions, and results from
the included studies were extracted into pre-
specified Microsoft Word extraction grids.
Quality Assessment
The quality of the included studies was assessed
using the Purpose, Respondents, Explanation,
Findings, Significance (PREFS) checklist, a tool
specifically designed to assess the quality of
preference studies [24]. The quality of each
study was assessed by a single individual, with
the conclusions regarding quality confirmed
independently by a second individual; any dis-
crepancies were discussed, and final decisions
were made by a third individual where
necessary.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
RESULTS
Study Selection
A total of 1110 records from database searches
and 990 records from congresses and SLR bibli-
ographies were screened. In total, 26
publications reporting on 21 unique studies
were included in this SLR (Fig. 1).
Study Characteristics
Of the 21 included studies, 10 reported on the
treatment of NETs [25–33], 10 reported the
treatment of acromegaly [34–43], and one
reported both [44]. The included studies were
conducted using a range of study designs, most
commonly including open-label trials
[25, 27, 34, 37], and prospective observational
studies [25, 31, 39, 43] among others (Table 1).
Group comparison studies compared experi-
ence between patients on parallel treatment
arms [25, 26, 28, 29, 31, 32, 36, 41–44] whereas
crossover studies reported the experience of
patients who switched from one SSA to the
other [34, 35, 37, 38, 40]. Patients switched
from OCT LAR to LAN treatment in all crossover
studies. Most studies (n = 19) were conducted in
the USA and/or Europe (Table 1).
All but one of the studies included LAN
[25–44]; 17 compared LAN with OCT
[25, 26, 28, 29, 31–38, 40–42, 44], four studies
investigated different formulations or adminis-
tration methods of LAN exclusively
[30, 33, 39, 43], and a single study exclusively
investigated different formulations of OCT [27].
Most studies did not specifically aim to inves-
tigate patient or HCP perspectives of SSA treat-
ments; efficacy and tolerability of treatment
were often the primary outcomes in these cases,
and treatment perspective was collected as a
secondary or exploratory outcome. The major-
ity of studies (n = 12) used structured ques-
tionnaires or surveys to elicit patient or HCP
treatment perspectives or preference
[25, 26, 28, 30, 31, 36, 38–41, 43, 44], though
these were not validated instruments, and
informal patient questioning was also a com-
mon approach (n = 5 ) [27, 34, 35, 37, 42].
Methods less frequently employed included use
of a patient–clinician shared decision-making
framework [29, 33], and a Delphi panel [32]. As
such, where preference was not explicitly
reported, the independent investigators
reviewing the studies in this SLR assessed the
statistical and numerical comparisons presented
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in each study. These comparisons were used to
determine which, if any, of the two treatments
was associated with the more favorable out-
come, such as lowest level of anxiety or fewest
technical problems, for example. Including
preference, nine key outcomes in treatment
experience were identified (Table 2). Here, we
focus on studies in which respondents had
direct experience of SSA treatment (rather than
anticipated preference) and where statistical or
numerical comparisons were provided (rather
than qualitative comparisons).
Treatment-Specific Preference
Of the 21 studies included in this SLR, five
crossover studies explicitly reported the prefer-
ences of patients who had direct experience of
both LAN and OCT LAR treatment (Table 3)
[34, 35, 37, 39, 40]. LAN was preferred in four of
the five studies that reported patient preference
as an outcome [34, 37, 39, 40]. All crossover
studies included patients who switched from
OCT LAR to LAN with the standard 28-day
dosing interval for each treatment.
Salvatori et al. reported that 81.3% of
patients preferred LAN in comparison with
12.5% for OCT LAR (n = 33, p = 0.0001), based
on a structured questionnaire, though reasons
for preference were not reported [38]. Alex-
opoulou et al. reported that 17/25 (68%)
patients with acromegaly chose LAN by infor-
mal opinion, whereas 2/25 (8%) preferred OCT
LAR; 6/25 (24%) patients did not report treat-
ment preference [34]. Reduced pain at the
injection site and fewer technical problems
following LAN injection were deemed by
investigators in this study to influence patient
choice [34].
Fig. 1 PRISMA diagram for included studies. CDSR
Cochrane Database of Systematic Reviews, CENTRAL
Cochrane Central Register of Controlled Trials, DARE
Database of Abstracts of Reviews of Effects, HCPs
healthcare practitioners, NETs neuroendocrine tumors,
PRISMA Preferred Reporting Items for Systematic
Reviews and Meta-Analyses
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Neggers et al. included three study arms,
whereby patients with acromegaly were swit-
ched from OCT LAR 4-week dosing interval to
LAN with either a 4-week dosing interval or a 6-
or 8-week extended dosing interval (EDI) [37].
LAN was preferred over OCT LAR in all treat-
ment regimens. At week 48, 53/68 (77.9%)
patients in the 6-week EDI group preferred LAN,
vs 10/68 (14.7%) who preferred OCT LAR; and
24/26 (92.3%) patients in the 8-week EDI group
preferred LAN, vs 2/26 who preferred the OCT
LAR 4-week interval [37]. Although this study
sought to investigate the impact of EDIs on
treatment preference, notably, 10/13 (76.9%)
patients chose LAN when administered with the
same 4-week dosing interval used for their pre-
vious OCT LAR treatment; just 2/13 (15.3%)
patients chose OCT LAR and 1/13 (7.7%) had no
preference (reasons for preference were not
reported) [37]. Schopohl et al. conducted a
similar study in which patients with acromegaly
(n = 33) switched from OCT LAR with standard
dosing interval to LAN with standard dosing
interval and EDI groups [40]. Preference for LAN
Table 2 Key outcomes relating to patient treatment experience
Outcome Number of studies Number of
patients
Favored SSAb
Patient preference 5 (all switch)a 10–112 LAN (9 4)
[34, 37, 39, 40]
OCT LAR (9 1) [35]
Anxiety/‘‘emotional quality’’ of
injections
2 (group comparisons) 119–120 LAN (9 2) [25, 26]
Technical problems with injections 4 (2 switch, 2 group
comparisons)
25–119 LAN (9 4)
[26, 28, 34, 43]
Satisfaction/‘‘expectations met’’ 2 (group comparisons) 44–102 LAN (9 1) [43]
NP (9 1) [31]
Time associated with injections 2 (group comparisons) 44–51 LAN (9 1) [28]
NP (9 1) [31]
Injection-associated pain 3 (2 switch, 1 group
comparison)
33–195 LAN (9 3) [34, 38, 41]
Convenience of injections 2 (1 switch, 1 group
comparison)
33–119 LAN (9 2) [26, 38]
Perceived effectiveness 1 (switch) 102 LAN [43]
Indirect costs 1 (switch) 26 LAN [30]
LAN lanreotide autogel/depot, NP no preference/favored SSA, OCT LAR octreotide long-acting release, SSA somatostatin
analog
a Switch refers to studies where patients had direct experience with both LAN and OCT, having switched from one
treatment to the other either prior to or during the study
b Aside from preference, the favored SSA was determined by the independent reviewers on the basis of the data included
within each study. Where statistical comparisons were performed and found to be non-significant, this was reported as NP;
a favored SSA was determined on the basis of numerical comparisons in studies where statistical analyses were not
performed
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Table 3 Treatment specific preference outcomes
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Table 3 continued
EDI extended dosing interval, GEP gastroenteropancreatic, HCP healthcare practitioner, ITT intention-to-treat, LAN
lanreotide, LAR long-acting release, NETs neuroendocrine tumors, NR not reported, OCT octreotide, SSA somatostatin
analog
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was higher overall; LAN was preferred in both
the 6- and 8-week EDI groups compared with
OCT LAR (63.6% vs 18.2%, and 57.1% vs 28.6%,
respectively) [40]. However, preference was
higher for OCT LAR over the standard LAN
4-week dosing interval group (41.2% vs 11.8%)
[40].
OCT LAR was preferred overall in one cross-
over study, where 6/10 patients with acrome-
galy cited fewer adverse effects (such as nodules
at the administration site) and greater perceived
efficacy compared with LAN [35].
Just two studies specifically reported HCP
preferences (Table 3) [36, 44]. A multicenter
opinion study in patients with NETs or acro-
megaly reported HCP preference when HCPs
had experience administering both SSAs [44].
LAN was preferred in this study because of the
attributes of a LAN injection syringe over OCT
LAR, such as faster and smoother administra-
tion with lower risk of needle clogging, as well
as the option for patients to self-inject using
this syringe [44]. Though direct experience with
either SSA was unclear, in one study where
endocrinologists (n = 196) completed an online
survey, HCPs reported preference for OCT LAR
(47.1%; n = 92) over LAN (32.2%; n = 63) as
their postoperative adjunctive medical therapy
of choice, deemed by the study’s authors to be
based on the longer period of market autho-
rization of OCT LAR compared with LAN,
although this varies between continents [36].
Proximal Factors in Treatment Experience
Outcomes commonly emerging as aspects that
influence preference or treatment experience
may be divided into proximal and distal factors.
Proximal factors refer to the practicalities and
immediate aspects of treatment, such as those
surrounding method of administration, while
distal factors are more conceptual and include
emotional aspects of treatment experience, and
preference itself.
Injection-Associated Pain
Injection-associated pain was reported as an
outcome in three studies [34, 38, 41], all of
which reported LAN as the favored treatment as
a result of less injection-associated pain com-
pared with OCT LAR injections. Of 33 patients
with acromegaly who switched from OCT LAR
to LAN treatment in the Salvatori et al. study,
more patients reported that LAN injection was
not painful at week 24 vs the OCT injection at
week 0 (the final OCT injection prior to
switching), compared using a McNemar’s test
(50.0% vs 25.0% of patients, respectively;
p = 0.0201) [38]. Among those who did report
pain, patients described the LAN and OCT LAR
injections as ‘‘somewhat painful’’ (43.8% vs
59.4%; p = NR), ‘‘moderately painful’’ (6.3% vs
6.3%; p = NR), or ‘‘very painful’’ (0.0% vs 9.4%;
p = NR) [38].
One group comparison study found that
patients with acromegaly (n = 83 prescribed
LAN; n = 112 prescribed OCT LAR) considered
the overall injection burden to be similar for the
two treatments [41]. The authors found small
but statistically significant differences in pain
and other injection site reactions; OCT LAR
injections were associated with slightly greater
pain at the injection site hours and days after
the injection (hours mean score [scale 0–3], 0.7
vs 0.6 for LAN, p = 0.05; days mean score [scale
0–3], 0.5 vs 0.3 for LAN, p = 0.0007). However,
LAN injections were associated with the devel-
opment of nodules, swelling, bruising, and
dermatitis (mean score [scale 0–3], 0.8 vs 0.5 for
OCT, p = 0.0008) [41]. In one crossover study
also in acromegaly, patients reported signifi-
cantly superior immediate local tolerability at
the injection site with LAN injections compared
with OCT LAR [34]; 76% (n = 19) of patients
reported mild-to-moderate pain at the injection
site with OCT LAR, vs 12% (n = 3) reporting
local pain after LAN injection.
Technical Problems with Injecting
Technical problems with injecting, such as
needle clogging and difficulty in completing
dose administration, were reported as an out-
come in four studies [26, 28, 34, 43]. LAN
injections were favorable in all four studies,
with markedly fewer technical problems repor-
ted compared with OCT LAR injections. Alex-
opoulou et al. reported results from 25 patients
with acromegaly who experienced treatment
with LAN after switching from OCT LAR [34].
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Patients informally gave their opinion, with the
majority recalling the occurrence of minor or
major technical problems for at least one of
their six most recent OCT LAR injections,
despite injections being administered by expe-
rienced paramedical staff (60/150 injections
reported by 19 patients) [34]. By contrast, no
technical problems were reported during any
LAN injections (p\0.001) [34]. Geilvoet et al.
carried out a survey designed for patients with
NETs with satisfaction-related theorems with a
five-point Likert scale, multiple choice, and free
text [28]. The survey revealed that 52% of
patients treated with OCT LAR (n = 23) experi-
enced injection problems, compared to 17% of
patients treated with LAN (n = 28) [28].
Witek et al. used a crossover study for
patients with acromegaly to assess technical
problems related to treatment administration
[43]. Measured by a visual analog scale (VAS),
whereby ‘‘no technical problems’’ was coded as
0, and ‘‘technical problems’’ was coded as 100,
patients (n = 102) reported fewer technical
problems related to the administration of LAN
(final mean VAS 5.3) compared with OCT LAR
(mean VAS 37.6) [43]. Almquist et al. used a
survey questionnaire to assess recent SSA injec-
tion experiences of patients with GEP-NETs,
including technical problems with injecting
[26]. Twelve out of 66 (18%) patients treated
with OCT LAR reported problems with their
most recent injection, whereas none of the 53
patients receiving LAN treatment reported any
problems with their most recent injection
(p = 0.001) [26]. From the HCP perspective,
HCPs in one time and motion study involved
with treatment administration indicated con-
cerns over OCT LAR, due to longer time to
prepare as well as increased risk of needle clog-
ging (p = 0.034) and device failures (p = 0.057)
[31].
Distal Factors in Treatment Experience
Anxiety/‘‘Emotional Factors’’
Emotional factors were a notable outcome
reported among patients when examining SSA
treatment perspectives. Two studies were iden-
tified reporting such outcomes, both of which
reported group comparisons, with patients
experiencing either LAN or OCT LAR treatment;
both studies favored LAN [25, 26]. Adams et al.
asked 120 patients to grade the ‘‘emotional
quality’’ of their injection experience, where
LAN injections were significantly associated
with a positive injection experience vs OCT LAR
injections (p\0.001) [25]. The questionnaire
used by Almquist et al. also assessed levels of
anxiety prior to injection [26]. Fewer patients
reported moderate-to-high anxiety with LAN
injections vs OCT LAR (2% vs 11%, n = 119;
p = NR) [26].
Satisfaction/‘‘Expectations Met’’
One time and motion study reported statistical
comparisons for satisfaction between LAN and
OCT LAR in terms of treatment delivery attri-
butes from the perspective of both patients and
HCPs [31]. Of the 22 patients included for each
treatment arm, 20 (90.9%) patients treated with
LAN reported that all or most of their expecta-
tions had been met compared with 18 (81.8%)
patients treated with OCT LAR (p = 0.25) [31].
HCPs involved in preparing and delivering SSAs
indicated significantly higher satisfaction with
LAN vs OCT LAR (median satisfaction score 5 vs
4, p = 0.006) [31].
Convenience
Three studies reported statistical comparisons
between LAN and OCT regarding the time taken
for treatment administration and patient wait-
ing time in the clinic prior to their injection
[28, 31, 44]. Geilvoet et al. concluded from a
patient survey that visits by nurses administer-
ing LAN (n = 28) were significantly shorter than
for OCT LAR (n = 23; p = 0.048) [28]. Ryan et al.,
using a time and motion study comparing
treatment delivery attributes between SSAs,
reported that patient waiting times (from clinic
check-in to check-out) were similar for LAN and
OCT LAR. The median total waiting time per
visit was 6.2 min shorter for patients receiving
LAN than for those receiving OCT LAR
(25.0 min vs 31.2 min, respectively), though
this comparison did not reach statistical signif-
icance (p = 0.734; n = 43) [31].
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From the HCP perspective, Ryan et al. also
reported that there was a mean reduction of
3.7 min of treatment delivery time in favor of
LAN (2.5 [95% confidence interval (CI)
2.0–3.1] min) vs OCT LAR (6.2 [95% CI
4.4–7.9] min, p = 0.001) [31]. In an opinion
study where syringe attributes were rated by 77
nurses via a questionnaire, Adelman et al. found
that injection preparation and administration
time were significantly shorter with the LAN
syringe than OCT LAR (p\0.01) [44]. This
study also reported a significant difference in
mean score for ease/convenience of preparation
and injection, ranked among the most impor-
tant attributes by 70% of nurses, for the LAN
syringe (rated 9.4/10) and OCT LAR (rated 3.8/
10, p\0.05) [44]. In another study, comparing
HCP-administered injections with LAN vs OCT
LAR, LAN injections were judged by the study
investigators to be ‘‘much easier’’ or ‘‘easier’’ for
57.1% of 37 patients, ‘‘the same’’ for 17.1%,
‘‘more difficult’’ for 22.9%, and ‘‘much more
difficult’’ for 0.0% [40]. The most frequently
cited reasons for investigator preference for LAN
were ease of injection (51.4%), being time-sav-
ing (45.7%) and patient preference (45.7%) [40].
EDIs
Four studies reported that patients with acro-
megaly indicated a greater preference for longer
dosing intervals vs shorter intervals
[27, 37, 40, 42]. In two studies in patients with
acromegaly initially treated with OCT LAR
(dosing interval of 28 days) who then switched
to LAN (42- or 56-day intervals), over 55% of
patients in both studies expressed a preference
for the EDIs of LAN (numerical comparisons
only) [37, 40]. However, one of these studies
also reported that a higher proportion of
patients demonstrated a preference for a LAN
dosing interval of 42 days compared with
56 days (63.6% vs 57.1%), although no statisti-
cal comparisons were performed [40]. The
preference for the 56-day interval was higher
when investigator preference was also taken
into account [40]. The remaining two older
studies compared short-acting with long-acting
formulations; one study included patients
switching from daily subcutaneous octreotide
injections to monthly intramuscular octreotide
LAR [27], and the other included patients
switching from daily subcutaneous octreotide
injections to a lanreotide sustained release
microsphere formulation, administered by
intramuscular injection every 7–14 days [42].
The longer-acting formulations with longer
intervals between doses were preferred in both
studies [27, 42].
Self-/Partner-Injectable Treatment with LAN
Self- or partner-injection with LAN was investi-
gated in two studies in patients with acrome-
galy and one in NETs [30, 38, 39]. Self- or
partner-injectable treatment was generally
favored compared with attending a medical site
or receiving LAN injections administered by
HCPs. Johanson et al. reported that reasons
pertained to increased independence and con-
venience, especially for patients living in
remote locations. Indirect costs associated with
SSA treatments for patients or their caregivers
were also estimated on the basis of
patient/partner time for travel and injection;
one HCP-administered LAN injection was esti-
mated to cost €7.95, while one self-injection
was estimated to cost €0.10, on account of
patients not having to travel or take time off
work to be treated [30].
Quality Assessment
A quality assessment was conducted for each
study using the PREFs checklist (Table 4) [24].
Just one of the included studies sufficiently
answered all domains of the checklist [44], and
six studies answered four out of the five
domains [29, 31, 33, 41, 43, 45], most com-
monly not including statistical comparisons
[29, 33, 43, 45]. Most of the included studies did
not explicitly aim to investigate SSA preference
and, as such, purpose in relation to preferences
and significance was not a strong domain across
studies. Methods of assessment in the context of
treatment experience and preferences were
reported inconsistently; some studies specifi-
cally stated their assessments as part of their
methodology, while several did not, or assess-
ment methods were unclear. Statistical com-
parisons were used to assess differences between
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the SSAs in only 8/21 studies, with the majority
of studies making numerical comparisons. A
minority of studies explicitly reported prefer-
ence between SSAs, and the remainder often did
not report sufficient information relevant to
SSA treatment experience to clearly determine
which SSA was favored.
DISCUSSION
This SLR aimed to identify relevant evidence
describing treatment characteristics that impact
patient and HCP experience of long-acting,
first-generation SSAs in the treatment of NETs
or acromegaly. The 21 included studies had
varied scopes and used a wide range of quanti-
tative and qualitative designs, leading to con-
siderable heterogeneity across the reported
results. Within these studies, factors identified
to potentially impact treatment experience
included ease of administration and fewer
problems with injecting [26, 28, 35], less pain at
the injection site [34, 38], and emotional expe-
rience, or less anxiety, associated with injecting
[25, 26]. It is perhaps likely that these factors are
linked. For example, more problems with
injecting may cause pain at the injection site
due to re-injection, and more pain could lead to
increased anxiety when injecting.
Several factors surrounding mode of admin-
istration were identified as contributors to SSA
treatment experience, indicating that comfort,
convenience, and independence may also be of
particular importance in the management of
disease and treatment, especially among
patients. However, a large proportion of
patients who participated in the studies inclu-
ded in this SLR were prescribed LAN at the
standard 4-week interval, and their injections
were administered by HCPs; notably, three
studies reported patient preference for LAN over
OCT LAR when patients were receiving HCP
injections at the same dosing interval
[34, 37, 39]. It is therefore likely that the prox-
imal factors surrounding injections, such as
technical problems with injecting and injec-
tion-associated pain, are currently greater con-
tributors to patients’ treatment experience;
when distal factors did not differ between
treatment groups, LAN was most commonly
preferred or favored. It is interesting to consider
that future studies might reveal a shift towards
home-based healthcare, especially in the era of
the coronavirus disease 2019 (COVID-19) pan-
demic, and, as such, the option for self- or
partner-injection may become a more promi-
nent feature in treatment decision-making.
Furthermore, a recent study evaluating patient
experience using a LAN syringe introduced in
2019 indicated that use of newer injection
devices could further reduce pain and anxiety
for patients [46, 47].
Where study participants had direct experi-
ence of both SSAs, four of the five studies
reporting patient preference, and the only study
reporting HCP preference, reported preference
for LAN over OCT LAR. Among HCPs, prepara-
tion and administration of LAN were reported
to be quicker and simpler, presenting fewer
technical problems such as device clogging, in
comparison with OCT LAR [28, 31, 34, 40, 44].
An important caveat of the comparisons made
regarding technical problems in the studies
included in this SLR is that, since these studies
were conducted, a new solvent for OCT LAR
reconstitution and a LAN new syringe have
become available [18, 19]. However, in a recent
observational study, 4% of nurses (n = 96)
reported that purge problems (clogging) per-
sisted when injecting OCT LAR reconstituted
with the new solvent [48]. Further, in an inter-
national simulated-use study (PRESTO), also
completed since this SLR was conducted, most
nurses (88/90) expressed a ‘‘slight’’ or ‘‘strong’’
preference for the LAN new syringe vs the OCT
LAR syringe (with the latest excipient), citing
‘‘confidence the syringe will not be clogged’’ as
the most important attribute [49]. This factor
may also impact patients’ treatment experience;
a recent survey conducted in 2019 found that
patients’ overall SSA injection experience is also
impacted by the training and process knowl-
edge of their HCP, leading to variation in
patient satisfaction depending on the nurse
administering the SSA [50]. Advancements in
device usability and functionality for HCPs may
therefore help improve patient satisfaction with
injections.
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Table 4 Quality assessment
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Habit, effectiveness, and adverse effects of
LAN were found to contribute to patient pref-
erence for OCT LAR in one study [35]. Although
experience with LAN was unclear, HCPs repor-
ted preference for OCT LAR in a study con-
ducted in 2017, based on a longer period of
market authorization compared with LAN [36].
Overall, however, perceived efficacy was not
one of the main factors contributing to patient
or HCP preference in the majority of studies.
This finding aligns with previously reported
data indicating that the efficacy of the two SSAs
may be comparable in both acromegaly and
NETs [40, 51, 52], or other factors beyond
treatment efficacy, such as technical problems
when administering treatment and injection-
associated pain, may be more important to
patients’ overall treatment experience.
Several limitations within the captured
studies and SLR methodology should be con-
sidered when interpreting the results. In terms
of the assessment tools used in the identified
studies, there was a lack of standardization
across the included studies, and none employed
validated quality of life or utility measures,
limiting the conclusions that can be drawn
from any comparisons made. Although nine
studies did include statistical analyses, some of
these may not have used robust statistical
methods to ascertain significant differences,
and differences may not necessarily be clinically
significant in certain instances, despite
Table 4 continued
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statistical significance. Additionally, for several
of the outcomes assessed, including pain, anxi-
ety, and nodules, there was a lack of informa-
tion to clarify the relative burden of those
factors for patients. When assessing different
interventions experienced by the same patient,
recall of the first treatment is subject to bias.
This may be important when considering that
patients switched in the direction of OCT LAR
to LAN in all crossover studies and were not
blinded to the treatment received. This possible
bias would not be a concern in the 11 studies
with treatment arms running in parallel.
While seven of the studies included in this
SLR reported preference as an outcome, none of
the included studies specifically aimed to assess
patient/HCP preference. For the purpose of this
SLR, favored treatment among patients or HCPs
in a number of studies was inferred through
statistical significance or numerical compar-
isons of data on factors such as treatment
preparation and administration time, visit
times, technical problems, and side effects.
Although such factors are advantageous and
may drive preference, they are not necessarily
correlated with patient/HCP preference for one
intervention over another and, as such, should
be interpreted with caution. The SLR search
strategy excluded non-English-language full
texts, potentially restricting the identification
of all relevant evidence and limiting the global
relevance of the review findings; the included
studies were conducted in Western countries
and the conclusions of this SLR may not be
applicable for patients in Asian countries and
other global regions. Finally, as is to be expec-
ted, the manufacturers of the two SSAs have
sponsored much of the research identified in
our review. Truly independent research into
patient preferences is difficult to obtain.
CONCLUSIONS
This SLR has identified a moderate volume of
evidence describing the treatment perspectives
of patients with acromegaly and NETs, as well as
their HCPs. While highlighting the hetero-
geneity in the way that treatment preferences
have previously been reported, a number of
common outcomes underlying treatment
experience, including injection-associated pain,
emotional quality of injections, time and con-
venience of treatment administration, and
patient independence and autonomy, were
identified. Future research should be specifically
designed to assess patient preference and to
determine which factors contribute the most to
positive patient and HCP experience. Studies
should also utilize a common framework or
validated reporting instrument to allow out-
comes reported across studies to be pooled and
analyzed more robustly. The findings of this SLR
provide a basis that could be used to inform
development of decision-making criteria, con-
sidering the patient perspective when initiating
long-acting SSA treatment.
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14. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in
metastatic enteropancreatic neuroendocrine
tumors. NEJM. 2014;371:224–33.
15. Lau SC, Abdel-Rahman O, Cheung WY. Improved
survival with higher doses of octreotide long-acting
release in gastroenteropancreatic neuroendocrine
tumors. Med Oncol. 2018;35:123.
16. Rinke A, Müller HH, Schade-Brittinger C, et al.
Placebo-controlled, double-blind, prospective, ran-
domized study on the effect of octreotide LAR in
the control of tumor growth in patients with
metastatic neuroendocrine midgut tumors: a report
from the PROMID Study Group. J Clin Oncol.
2009;27:4656–63.
17. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy
and safety of prolonged-release lanreotide in
patients with gastrointestinal neuroendocrine
tumors and hormone-related symptoms. J Clin
Oncol. 1999;17:1111.
18. Somatuline Depot (lanreotide) injection prescribing
information (2019). https://www.accessdata.fda.
gov/drugsatfda_docs/label/2019/022074s024lbl.
pdf. Accessed 4 Jan 2021.
19. Sandostatin LAR Depot prescribing information
(2019). https://www.accessdata.fda.gov/drugsatfda_
docs/label/2019/021008s043lbl.pdf. Accessed 4 Jan
2021.
20. Troconiz IF, Cendros JM, Peraire C, et al. Population
pharmacokinetic analysis of lanreotide autogel in
healthy subjects: evidence for injection interval of
up to 2 months. Clin Pharmacokinet. 2009;48:
51–62.
21. Valery C, Paternostre M, Robert B, et al. Biomimetic
organization: octapeptide self-assembly into nan-
otubes of viral capsid-like dimension. Proc Natl
Acad Sci USA. 2003;100:10258–62.
22. Sandostatin LAR. Summary of product characteris-
tics (2018). https://www.medicines.org.uk/emc/
product/1038/smpc. Accessed 4 Jan 2021.
23. EMC. Octreotide 100 micrograms/1ml solution for
injection SmPC (2019). https://www.medicines.org.
uk/emc/product/373/smpc. Accessed 4 Jan 2021.
24. Joy SM, Little E, Maruthur NM, et al. Patient pref-
erences for the treatment of type 2 diabetes: a
scoping review. Pharmacoeconomics. 2013;31:
877–92.
25. Adams J, Ray D, Willmon R, et al. Living with
neuroendocrine tumors: assessing quality of life
(QoL) through a mobile application. J Clin Oncol.
2018;36. https://doi.org/10.1200/JCO.2018.36.4_
suppl.359.
26. Almquist M, Myrenfors P, Strom T, et al. STREET—
somatostatin treatment experience trial. Neuroen-
docrinology. 2017;105(Suppl 1):191.
27. Garland J, Buscombe JR, Bouvier C, et al. Sando-
statin LAR (long-acting octreotide acetate) for
malignant carcinoid syndrome: a 3-year experience.
Aliment Pharmacol Ther. 2003;17:437–44.
28. Geilvoet W, Feelders R, De Herder WW. Patient
satisfaction regarding home injection service for
somatostatin analogues: a survey among patients
with a neuroendocrine tumour. Neuroendocrinol-
ogy. 2017;105(Suppl 1):198.
29. Goetghebeur M, Samaha D, Khoury H, et al. To
treat or watch? Identifying drivers of decisions for
patients with GEP-NET using reflective multi-crite-
ria decision analysis. Neuroendocrinology.
2017;105(Suppl 1):235.
30. Johanson V, Wilson B, Abrahamsson A, et al. Ran-
domized crossover study in patients with neuroen-
docrine tumors to assess patient preference for
lanreotide autogel given by either self/partner or a
health care professional. Patient Prefer Adherence.
2012;6:703–10.
Adv Ther (2021) 38:969–993 991
31. Ryan P, McBride A, Ray D, et al. Lanreotide depot/
autogel vs. octreotide LAR for patients with
advanced gastroenteropancreatic neuroendocrine
tumours: an observational time and motion analy-
sis. In: NANETS 11th annual multidisciplinary NET
symposium, 04–06 Oct 2018, Seattle, WA, USA.
2018;P-12:211–2. https://nanets.net/abstracts-
archive/2018/948-abstract-p12/file. Accessed 4 Jan
2021.
32. Sevilla I, Segura A, Capdevila J, et al. Management
of controversial gastroenteropancreatic neuroen-
docrine tumour clinical situations with somato-
statin analogues: results of a Delphi questionnaire
panel from the NETPraxis program. BMC Cancer.
2016;16:858.
33. Wagner M, Samaha D, Cuervo J, et al. Applying
reflective multicriteria decision analysis (MCDA) to
patient-clinician shared decision-making on the
management of gastroenteropancreatic neuroen-
docrine tumors (GEP-NET) in the Spanish context.
Adv Ther. 2018;35:1215–31.
34. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy
and tolerability of lanreotide autogel therapy in
acromegalic patients previously treated with
octreotide LAR. Eur J Endocrinol. 2004;151:317–24.
35. Andries M, Glintborg D, Kvistborg A, et al. A
12-month randomized crossover study on the
effects of lanreotide autogel and octreotide long-
acting repeatable on GH and IGF-l in patients with
acromegaly. Clin Endocrinol. 2008;68:473–80.
36. Apaydin T, Ozkaya HM, Keskin FE, et al. Daily life
reflections of acromegaly guidelines. J Endocrinol
Investig. 2017;40:323–30.
37. Neggers SJ, Pronin V, Balcere I, et al. Lanreotide
autogel 120 mg at extended dosing intervals in
patients with acromegaly biochemically controlled
with octreotide LAR: The LEAD study. Eur J Endo-
crinol. 2015;173:313–23.
38. Salvatori R, Nachtigall LB, Cook DM, et al. Effec-
tiveness of self- or partner-administration of an
extended-release aqueous-gel formulation of lan-
reotide in lanreotide-naive patients with acrome-
galy. Pituitary. 2010;13:115–22.
39. Salvatori R, Woodmansee WW, Molitch M, et al.
Lanreotide extended-release aqueous-gel formula-
tion, injected by patient, partner or healthcare
provider in patients with acromegaly in the United
States: 1-year data from the SODA registry. Pitu-
itary. 2014;17:13–21.
40. Schopohl J, Strasburger CJ, Caird D, et al. Efficacy
and acceptability of lanreotide autogel 120 mg at
different dose intervals in patients with acromegaly
previously treated with octreotide LAR. Exp Clin
Endocrinol Diabetes. 2011;119:156–62.
41. Strasburger CJ, Karavitaki N, Stormann S, et al.
Patient-reported outcomes of parenteral somato-
statin analogue injections in 195 patients with
acromegaly. Eur J Endocrinol. 2016;174:355–62.
42. Verhelst JA, Pedroncelli AM, Abs R, et al. Slow-re-
lease lanreotide in the treatment of acromegaly: a
study in 66 patients. Eur J Endocrinol. 2000;143:
577–84.
43. Witek P, Mucha S, Ruchala M. Patient satisfaction
and preferences of lanreotide autogel treatment in
acromegaly. Endokrynologia Polska. 2016;67:
572–9.
44. Adelman DT, Burgess A, Davies PR. Evaluation of
long-acting somatostatin analog injection devices
by nurses: a quantitative study. Med Devices
(Auckl). 2012;5:103–9.
45. Wagner M, Samaha D, Khoury H, et al. Develop-
ment of a framework based on reflective MCDA to
support patient-clinician shared decision-making:
the case of the management of gastroenteropan-
creatic neuroendocrine tumors (GEP-NET) in the
United States. Adv Ther. 2018;35:81–99.
46. Adelman DT, Van Genechten D, Megret CM, et al.
Co-creation of a lanreotide autogel/depot syringe
for the treatment of acromegaly and neuroen-
docrine tumours through collaborative human
factor studies. Adv Ther. 2019;36:3409–23.
47. Walter T, Eskenazi M, Rama N, et al. Patient and
nurse satisfaction with the new lanreotide autogel
pre-filled syringe in neuroendocrine tumors (NET):
a prospective study (SONATE). In: ENETS 17th




a-prospective-study-sonate.html. Accessed 4 Jan
2021.
48. Cadiot G, Coriat R, Raverot G, et al. EvAluation de
Satisfaction Infirmière (Nurse satisfaction evalua-
tion). Observational study of the preparation and
intramuscular administration of the previous and
new long-acting release octreotide LAR formulation
(EASI). In: ENETS 17th annual conference, 11–13





tide-lar-formulation-easi.html. Accessed 4 Jan 2021.
49. Adelman DT, Truong-Thanh X, Feuilly M, et al.
Evaluation of nurse preferences between the
992 Adv Ther (2021) 38:969–993
lanreotide autogel new syringe and the octreotide
long-acting release syringe: an international simu-
lated-use study (PRESTO). Adv Ther. 2020;37:
1608–19.
50. Darden C, Ray D, Goldstein G, et al. Satisfaction
survey of administration modes for long-acting
somatostatin analog therapy in patients with neu-
roendocrine tumors. In: NANETS 12th annual
multidisciplinary NET symposium, 03–05 Oct 2019,






51. Tutuncu Y, Berker D, Isik S, et al. Comparison of
octreotide LAR and lanreotide autogel as post-op-
erative medical treatment in acromegaly. Pituitary.
2012;15:398–404.
52. Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide
long-acting repeatable and lanreotide autogel are
equally effective in controlling growth hormone
secretion in acromegalic patients. Eur J Endocrinol.
2004;150:489–95.
Adv Ther (2021) 38:969–993 993
